{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-026642","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.179992+00:00","generated_at":"2026-05-15T04:51:40.276472+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Vanda Pharmaceuticals appoints Dr. Charles Duncan to Board of Directors effective April 22, 2026","bullets":["Board expands from six to seven members; Duncan appointed as Class II director with term ending at 2026 annual meeting.","Initial RSU award of $390,000 vests quarterly over four years; annual cash retainer of $50,000.","Additional annual RSU award of $260,000 after each annual meeting starting 2026, vesting one year later.","Duncan previously Managing Director at Cantor Fitzgerald, covering >70 biotech companies; founded Sulci Advisors in Sep 2025.","Duncan cites recent approvals of NEREUS and BYSANTI, label expansion for Fanapt, and pipeline catalysts over next 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-026642","json":"https://secwatch.observer/filing/0001628280-26-026642.json","markdown":"https://secwatch.observer/filing/0001628280-26-026642.md","text":"https://secwatch.observer/filing/0001628280-26-026642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/0001628280-26-026642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/vnda-20260422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:51:40.276472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}